Series B Biotech companies in Boston

Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com.Community Guidelines: bit.ly/FMICommunityGuidelines

• Series B
• 1.8k employees
• Founded 2010

Empatica is a full-stack digital health company and an MIT spin-off, with offices in Boston (MA), Milan (Italy), and Seoul (South Korea). We specialize in the development, production, and deployment of medical-grade wearables and digital biomarkers, powered by an AI-driven platform designed for continuous health monitoring and the early detection of medical conditions.The FDA-cleared Empatica Health Monitoring Platform consists of the medical-grade EmbracePlus and EmbraceMini wearables and the world’s largest selection of validated digital measures, enabling thousands of institutional partners to remotely collect patient health data, in trials and studies on sleep, stress, epilepsy, and more.Empatica’s Embrace wearable was the world’s first FDA-cleared smartwatch in neurology to detect epileptic seizures. In 2024, we launched its successor, EpiMonitor, with all of the most loved features of Embrace and even more. EpiMonitor is an all-in-one wearable and smartphone application solution for detecting possible generalized tonic-clonic seizures, alerting caregivers during emergencies, and monitoring epilepsy. It is the only FDA-cleared wrist-worn wearable and app combination for epilepsy monitoring in the US.

• Series B
• 130 employees
• Founded 2011

Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to unlock the full potential of genetic medicines. Strand is applying its proprietary Signal Stack platform, which integrates EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery, and logic-driven SignalLock genetic circuits to enable precise control of therapeutic activity across tissues and cell types and overcome foundational limitations in targeting, durability, and safety. Strand is advancing a pipeline with an initial focus on oncology and autoimmune disease. Its initial program, STX-001, an intratumorally delivered LNP-encapsulated self-replicating RNA expressing IL-12, has demonstrated preliminary evidence of systemic immune activation and anti-tumor activity in patients with advanced solid tumors who have progressed on prior therapies. Building on this early clinical validation, intravenously delivered STX-003 is designed for tumor-targeted expression and avoidance of off-target expression. STX-003, which is expected to enter the clinic in mid-2026, has the potential to be a major step forward for the fields of genetic medicine and oncology. Strand is also advancing STX-005, an in vivo CAR-T program designed to enable controlled, durable expression and repeat dosing. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA.

• Series B
• 124 employees
• Founded 2017

Asimov builds tools to program living cells. By integrating mammalian synthetic biology, computer-aided design, and machine learning, our multi-disciplinary team is advancing the design and manufacture of biologics and gene therapies.

• Series B
• 119 employees
• Founded 2017

GALY is growing the future.

 We are an army of dreamers that believe scientists are artists of a new era. We are envisioning a world where we can still produce sought-after materials without the physical turmoil we place on disadvantaged people and the planet. That is why we are revolutionizing the way we produce goods today and therefore sparking a much more sustainable form of doing agriculture.
 However, nobody takes innovation seriously until you scale it. We are on it! By developing intelligent scale-up strategies with cotton cells, as the in-vitro cotton production market has never been done on an industrial scale, we are capable of doing something truly new.
With this mind, we gather a team of highly diverse subjects, ranging from genetic engineering, plant cell culture, bioreactor development, mathematics, statistics, designers, high-performance automation, stylists, illustrators, creative business development, marketing and branding strategies. A group with a strong sense of purpose on a mission to find ways to save our planet.
We are scientists. We are artists. We are creative.And we are inviting brands to follow our lead, in order to ensure our planet’s survival.

• Series B
• 82 employees
• Founded 2019